Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies to millions of patients living with chronic skin conditions. Sonoma believes its products, which are sold throughout the United States and internationally, have improved patient outcomes for more than five million patients globally by treating and reducing certain topical skin diseases including acne, atopic dermatitis, scarring, infections, itch, pain and harmful inflammatory responses.
Sonoma Pharmaceuticals Presentation October, 2017
Jan 9, 2018
Sonoma Pharmaceuticals Receives Three New United Arab Emirates Regulatory Approvals: Acuicyn® for Management of Blepharitis, Microsafe® Oral Care for Mucositis and Sinudox® for Chronic Sinusitis
Dec 5, 2017
Sonoma Pharmaceuticals Announces Second FDA Approval to Add Antimicrobial Language to Alevicyn™ Gel Products for Management of Atopic Dermatitis
Nov 16, 2017
Sonoma Pharmaceuticals Announces FDA Approval of Expanded Indication for Alevicyn™ to Add Antimicrobial Language
This website contains forward-looking statements based on certain assumptions and expectations. For this purpose, any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties relating to our product development, success of clinical trials, obtaining the requisite regulatory approvals, market acceptance of our product, our ability to protect our intellectual property and future financial results. For a discussion of other factors that may cause Sonoma's actual results to differ from those projected, expressed or implied by the forward looking statements, please refer to the Company's Registration Statement on Form S-1 as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.